Sign In
Buy XENE
$53.46
+1.16 (+2.22%)
At Close: Jun 03, 2026
XENE Stock: Why It Increased Today
10:26pm, Wednesday, 06'th Oct 2021
The stock price of Xenon Pharmaceuticals Inc (NASDAQ: XENE) increased by over 6% today. This is why it happened.
Xenon Pharmaceuticals Raises $300M Via Equity
07:18am, Wednesday, 06'th Oct 2021
Xenon Pharmaceuticals Inc (NASDAQ: XENE) priced its underwritten public offering of 8.5 million shares and pre-funded warrants to purchase up to 1.7 million shares. The common share offer price of
Xenon Pharmaceuticals Announces Pricing of $300.0 Million Public Offering
09:54pm, Tuesday, 05'th Oct 2021
BURNABY, British Columbia, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the pricing of its underwritten publi
XENE Stock: Why It Substantially Increased This Week
07:30am, Tuesday, 05'th Oct 2021
The stock price of Xenon Pharmaceuticals Inc (NASDAQ: XENE) increased by over 100% this week. This is why it happened.
Is Xenon Pharmaceuticals a Good Stock to Buy Now?
05:42am, Tuesday, 05'th Oct 2021
Despite the big run-up yesterday, there could be enough fuel to push this biotech stock even higher.
Xenon Pharmaceuticals Announces Proposed Public Offering
04:08pm, Monday, 04'th Oct 2021
BURNABY, British Columbia, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritte
Pharma Stock Soars to Record Highs After Epilepsy Drug Study Results
01:32pm, Monday, 04'th Oct 2021
Xenon Pharmaceuticals Inc (NASDAQ:XENE) stock is soaring today, up 90.8% to trade at $29.76 at last glance, after the company met its main goal in a phase 2 study of its epilepsy treatment XEN1101.
Xenon Pharma Shares Jump After Epilepsy Treatment Phase 2 Data Meets Primary Endpoint
10:28am, Monday, 04'th Oct 2021
Xenon Pharmaceuticals Inc (NASDAQ: XENE) has reported topline results from the Phase 2b X-TOLE trial evaluating XEN1101 as an adjunctive treatment in adult patients with focal epilepsy. The trial m
Why Xenon Pharmaceuticals Stock Is Soaring Today
10:07am, Monday, 04'th Oct 2021
Xenon Pharmaceuticals Inc (NASDAQ: XENE) is trading significantly higher Monday after the company announced its phase 2 study of XEN1101 for the treatment of epilepsy met all primary and secondary en
Tesla Sets Delivery Records, but This Nasdaq Stock Was the Big Premarket Winner Monday
09:19am, Monday, 04'th Oct 2021
Markets are looking to open on a down note.
Why Xenon Pharmaceuticals Stock Is Screaming Higher Today
09:18am, Monday, 04'th Oct 2021
A positive mid-stage trial is powering this biotech stock higher today.
BURNABY, British Columbia, Oct. 03, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that Xenon management will host a
Are Options Traders Betting on a Big Move in Xenon (XENE) Stock?
09:57am, Monday, 20'th Sep 2021
Investors need to pay close attention to Xenon (XENE) stock based on the movements in the options market lately.
Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $10.0 Million Regulatory Milestone
08:30am, Wednesday, 08'th Sep 2021
Phase 2 Clinical Trial to Evaluate NBI-921352 for the Treatment of Focal-Onset Seizures in Adults Anticipated in 2021 Phase 2 Clinical Trial to Evaluate NBI-921352 for the Treatment of Focal-Onset Sei
Xenon Pharmaceuticals Strengthens Leadership Team with Appointment of Dr. Christopher Kenney as Chief Medical Officer
08:30am, Monday, 23'rd Aug 2021
BURNABY, British Columbia, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the appointment of Christopher Ken
